Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients
Table 4
Association of polymorphisms in antioxidative genes with NYHA class and LVEF reduction.
NYHA
LVEF reduction
SNP
Genotype
Class 1, (%)
Class 2, (%)
OR (95% CI)
OR (95% CI)adj
No, (%)
Yes, (%)
OR (95% CI)
PON1 rs854560
AA
33 (78.6)
9 (21.4)
Reference
38 (90.5)
4 (9.5)
Reference
AT+TT
51 (86.4)
8 (13.6)
0.58 (0.20-1.64)
0.301
0.61 (0.19-1.99)
0.416
54 (91.5)
5 (8.5)
0.88 (0.22-3.49)
0.885
PON1 rs662
AA
44 (81.5)
10 (18.5)
Reference
50 (92.6)
4 (7.4)
Reference
AG+GG
40 (85.1)
7 (14.9)
0.77 (0.27-2.22)
0.628
0.88 (0.27-2.84)
0.832
42 (89.4)
5 (10.6)
1.49 (0.38-5.90)
0.572
GSTP1 rs1138272
CC
69 (83.1)
14 (16.9)
Reference
75 (90.4)
8 (9.6)
Reference
CT+TT
15 (83.3)
3 (16.7)
0.99 (0.25-3.87)
0.984
0.88 (0.20-3.92)
0.862
17 (94.4)
1 (5.6)
0.55 (0.07-4.71)
0.586
GSTP1 rs1695
GG
36 (81.8)
8 (18.2)
Reference
38 (86.4)
6 (13.6)
Reference
GA+AA
48 (84.2)
9 (15.8)
0.84 (0.30-2.40)
0.750
0.84 (0.26-2.74)
0.773
54 (94.7)
3 (5.3)
0.35 (0.08-1.50)
0.157
CAT rs1001179
GG
58 (90.6)
6 (9.4)
Reference
58 (90.6)
6 (9.4)
Reference
GA+AA
26 (70.3)
11 (29.7)
4.09 (1.37-12.25)
0.012
4.14 (1.22-14.09)
0.023
34 (91.9)
3 (8.1)
0.85 (0.20-3.63)
0.830
HIF1A rs1154965
CC
71 (80.7)
17 (19.3)
Reference
81 (92.0)
7 (8.0)
Reference
CT+TT
13 (100.0)
0 (0.0)
/
0.118
11 (84.6)
2 (15.4)
2.10 (0.39-11.44)
0.389
Adj: adjusted for hyperlipidemia and body mass index. calculated using Fisher’s exact test. CI: confidence interval; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; OR: odds ratio.
